MYLAN INSTITUTIONAL INC. – Trademark Portfolio
Entity Type: 03
MYLAN INSTITUTIONAL INC. holds 23 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 22 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 9 trademarks are registered and 1 is pending. Notable registered marks include O, X, OGIVRI, ARIXTRA, and HYDROCOL. The owner is based in ROCKFORD, IL.
1718 NORTHROCK COURT
ROCKFORD, IL 61103
Showing of trademarks Trademarks
Trademark Classifications
MYLAN INSTITUTIONAL INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does MYLAN INSTITUTIONAL INC. have?
MYLAN INSTITUTIONAL INC. has 23 U.S. trademarks filed with the USPTO. Of these, 9 registered, 1 pending, 8 abandoned, 5 cancelled.
What trademark classes does MYLAN INSTITUTIONAL INC. file in?
MYLAN INSTITUTIONAL INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are MYLAN INSTITUTIONAL INC.'s most well-known trademarks?
MYLAN INSTITUTIONAL INC.'s registered trademark portfolio includes well-known marks such as O, X, OGIVRI, ARIXTRA, and HYDROCOL. These are among 9 currently registered trademarks in the portfolio.
What is MYLAN INSTITUTIONAL INC.'s trademark registration success rate?
MYLAN INSTITUTIONAL INC. has a 41% trademark registration rate, with 9 out of 22 resolved applications resulting in successful registration. Currently, 1 application is pending review.